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Under many inflammatory contexts, such as tumor progression, systemic and periph-
eral immune response is tailored by reactive nitrogen species (RNS)-dependent post-
translational modifications, suggesting a biological function for these chemical alterations.
RNS modify both soluble factors and receptors essential to induce and maintain a tumor-
specific immune response, creating a “chemical barrier” that impairs effector T cell infil-
tration and functionality in tumor microenvironment and supports the escape phase of
cancer. RNS generation during tumor growth mainly depends on nitric oxide production
by both tumor cells and tumor-infiltrating myeloid cells that constitutively activate essential
metabolic pathways of L-arginine catabolism.This review provides an overview of the poten-
tial immunological and biological role of RNS-induced modifications and addresses new
approaches targeting RNS either in search of novel biomarkers or to improve anti-cancer
treatment.
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INTRODUCTION
During tumor progression, cancer cells secrete factors, like
cytokines, chemokines, and metabolites (1, 2) that promote the
development of a flexible microenvironment able to induce a mod-
ification in anti-tumor immune response. Tumors, indeed, need
to shade and block out the effectors of the immune system in
order to keep on growing (3). For this purpose, neoplastic cells
release soluble factors that alter the physiological hematopoiesis
in bone marrow and secondary lymphoid organs, such as the
spleen, by promoting an unusual commitment of highly immuno-
suppressive immature myeloid cells that sustain tumor growth,
neovascularisation, and spreading to local and distant anatomical
sites (4, 5). These cells, which have been named myeloid-derived
suppressor cells (MDSCs) to highlight their common myeloid ori-
gin and immunoregulatory properties on tumor-specific effector
T lymphocytes, critically contribute to shape an immune privi-
leged environment (6). MDSCs represent a heterogeneous popu-
lation, which includes immature monocyte- and granulocyte-like
elements, and progressively engrafts the tumor and secondary lym-
phoid organs in many preclinical contexts, such as in transgenic
mouse models of autochthonous pancreatic adenocarcinoma (7).
Expansion of MDSCs has been described also in clinical studies
demonstrating an inverse correlation between MDSC levels and
cancer clinical stage and outcome (8, 9). The other predominant
and heterogeneous myeloid cell subset induced by tumor progres-
sion is represented by tumor-associated macrophages (TAMs),
which are classified in two distinct subgroups: classically acti-
vated, type 1 macrophages (M1) and alternatively activated, type
2 macrophages (M2) (10–14). In many solid cancers, tumor-
infiltrating macrophages are polarized toward an M2-phenothype
and promote tumor progression by sustaining tumor angiogene-
sis and providing essential growth factors. In agreement with their
pro-tumoral activity, the M2-like macrophage presence and loca-
tion within tumor is often correlated to a poor prognosis (15–17).
Tumor-derived soluble factors and tumor-associated myeloid cells
build up a “physical barrier” around the tumor cells, which pro-
tects them against the attack of cytotoxic T lymphocytes (CTL)
and natural killer (NK) cells (18). Moreover, both neoplastic
and tumor-associated myeloid cell metabolisms are responsible
for the consumption of essential nutrients required to sustain
lymphocytic activity, such as l-arginine (l-Arg), l-cysteine (l-
Cys), l-phenylalanine (l-Phe), and l-tryptophan (l-Trp) (5, 19):
depletion of these amino acids establishes an additional “chemical
barrier”around the tumor that affects T cell fitness (20–23). One of
the most essential component of this barrier is represented by the
diatomic radical nitric oxide (nitrogen monoxide, NO), which is
involved in a large spectrum of immune dysfunctions such as T cell
inhibition through the blockade of phosphorylation and activa-
tion of Janus kinase (JAK) 3, reduction of major histocompatibility
complex class II (MHCII) expression,and induction of T cell apop-
tosis (24). NO is endogenously generated by four isoforms of nitric
oxide synthase (NOS): mitochondrial-specific NOS (mtNOS),
neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2),
and endothelial NOS (eNOS or NOS3). The mtNOS, nNOS, and
eNOS are constitutively expressed in a variety of cell types and
are activated following a transient change in intracellular calcium
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concentration. On the contrary, iNOS is expressed in response to
several extracellular stimuli regulating distinct signaling pathways
and catalyzes NO production independently from intracellular cal-
cium concentration (25). Interestingly, iNOS enzyme is expressed
by M1-like macrophages and can be co-expressed with arginase-
1 (ARG1) in MDSCs, resulting in l-Arg reduced availability and
production of reactive nitrogen species (RNS) in tumor microen-
vironment. RNS affect not only the structure of individual proteins
but also modify the protein–protein interaction and function (26).
Thus, nitrogen-derived post-translational modifications (PTM)
result from either direct interaction with NO or after exposure
to RNS, a term that includes peroxynitrite (ONOO−), nitrogen
dioxide radical (NO2), and other nitrogen oxides and products
arising when NO reacts with reactive oxygen species (ROS) such
as superoxide anion (O2−) (27). RNS are commonly generated
in sub-cellular compartments such as the peroxidase-containing
secretory granules of neutrophils and eosinophils, the mitochon-
dria and endoplasmic reticulum of endothelial and smooth muscle
cells, and the vasculature (28). Under physiological conditions,
cells produce ROS through the mitochondrial electron transport
of aerobic respiration. At low levels, ROS are well tolerated by cells
thanks to enzymatic detoxifying systems like superoxide dismu-
tases (SOD) and glutathione S-transferase, which neutralize the
free radicals (29). Under pathological contexts (such as during sus-
tained inflammation), ROS reach high concentrations and become
toxic, thus affecting cellular metabolism by either direct oxidations
of macromolecules or after combining with NO to generate RNS.
The reaction between NO and O2− is extremely rapid and depends
on both redox environment and NO concentrations, producing
two distinct PTM: nitration or nitrosylation. An equal concen-
trations of NO and superoxide leads to peroxynitrite formation,
which can nitrate either free or protein-associated tyrosines to
form 3-nitrotyrosines; two- to three-fold excess of NO predomi-
nantly results in dinitrogen trioxide (N2O3) formation, the major
S-nitrosylating agent in the intracellular microenvironment (30).
A representation of the main RNS-generating pathways and
derived PTM is depicted in Figure 1.
Protein tyrosine nitration consists in the incorporation of a
nitro triatomic molecule (−NO2), generally in ortho position of
the phenol hydroxyl group. There are two main mechanisms lead-
ing to tyrosine nitration in vivo: the formation of peroxynitrite
and the production of NO2 by heme proteins (31). Peroxynitrite
chemistry is highly pH dependent. At physiological pH, NO reacts
with O2−, producing ONOO−. Nitration is maximal at physio-
logical pH (about pH 7.4) and its yield decreases quickly under
more acidic or basic conditions, whereas sulfhydryl oxidation
increases from pH 5 to 9 (32). Peroxynitrite-mediated tyrosine
nitration is also accelerated in the presence of transition metal
ions either in their free form (Cu2+, Fe3+, Fe2+), as complexes
involving protoporphyrin IX (hemin), chelators (cyanide (CN−),
or ethylenediaminetetraacetic acid (EDTA)) (33).
Nitration is commonly considered an irreversible modifica-
tion that can be removed only with protein turnover. However,
some papers describe the presence of denitrases in different tis-
sues and animal models making controversial this assumption:
for example, a denitrase activity was detected in rat and dog tis-
sues (34–36). Moreover, this denitrating activity was described
FIGURE 1 | Reactive nitrogen species-generating chemistry and PTM.
L-Arginine catabolism involves two main classes of enzymes, ARG and
NOS. ARG participates in the urea cycle, producing L-ornithine and urea,
while NOS generates nitric oxide and citrulline. L-Arginine deprivation by
ARG up-regulation results in NOS uncoupling and consequent production of
O−2 rather than NO. Superoxide is also produced by NOX enzyme, during
the transfer of electrons from NAD(P)H to molecular oxygen. Under
pathological contexts, such as cancer and sustained inflammation, NO and
O−2 levels raise and combine to generate a variety of RNS: equal
concentrations of NO and superoxide will lead to ONOO− formation and
subsequent protein nitration, while two- to three-fold excess of NO will
predominantly result in N2O3 production, a main S-nitrosylating agent.
in lipopolysaccharide (LPS)-activated macrophage lines (37, 38).
Interestingly a nitration reversible/enzymatic mechanism active
in the mitochondria after changes in O2 concentrations was also
identified (39). Since RNS-dependent PTM have critical effects
on protein function, the reversibility of the process may unveil a
crucial biological regulation mechanism for cellular metabolism.
The frequency of tyrosine occurrence in proteins is approximately
3–4 mol%, which is similar to other aromatic amino acid such
as phenylalanine (40). Tyrosine is a mildly hydrophobic amino
acid and so there is a relatively good probability that some tyro-
sine residues will be exposed to the solvent. Examination of the
nitration site in peroxynitrite-modified proteins revealed a prefer-
ence for tyrosine residues located in loop structures and paucity of
nitration in tyrosine residues located on β-strands; however, the
primary protein structure does not seem to be a discriminative
factor since no consensus sequence for tyrosine nitration has been
found so far (40). The addition of a nitro group to tyrosine confers
particular physicochemical properties to the modified amino acid,
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which may have important functional consequences. Three major
effects on protein function can be predicted due to tyrosine nitra-
tion: no alteration in protein function, loss of function, and gain of
function. For example, the plasma proteins α1-antichymotrypsin
and transferrin do not undergo any substantial function modifi-
cation following tyrosine nitration, either in vitro or in vivo (41);
on the contrary specific enzymes, as glutathione reductase (GR)
and protein kinase C, are inactivated by 3-nytrotyrosine forma-
tion (42). On the other hand, cytochrome c (43), fibrinogen (44),
protein kinase Cε (45), and microsomal glutathione S-transferase
1 (46) present an increased functionality following PTM.
In addition to nitration, NO could induce other important
modifications including protein S-nitrosylation. This is a cova-
lent PTM resulting from the coupling of a NO moiety with
the reactive thiol group of a cysteine residue to form an S-
nitrosothiol. Contrary to other PTM, such as phosphorylation or
ubiquitinylation, S-nitrosylation is not enzyme-dependent. Pro-
tein S-nitrosylation is reversibly controlled by S-nitrosylation and
denitrosylation reactions, which preserve a dynamic balance in
living systems. A number of studies have indicated that abnormal
S-nitrosylation is implicated in cancer development and progres-
sion as in head and neck squamous cell carcinoma (47), as well
as in response to some therapeutic and treatment options (48).
Indeed, several S-nitrosylated proteins have been identified to
be involved in various cancer-related events. Briefly, the B cell
lymphoma (Bcl)-2 S-nitrosylation, which occurs in Cys158 and
Cys229 residues, reduces its degradation through the ubiquitin–
proteasomal pathway exacerbating the BCL-2 anti-apoptotic effect
(49); the S-nitrosylation of apoptosis antigen 1 (Fas) on its Cys304
promotes Fas ligand-mediated apoptosis in cancer cells (50); the
S-nitrosylation of p53 prevents normal response to damaged DNA
(51); the S-nitrosylation of hypoxia inducible factor (HIF)-1α
exerts a pro-angiogenesis function in tumor progression and con-
fers resistance to radiotherapy (52); finally, the S-nitrosylation of
O6-alkylguanine-DNA alkyltransferase (AGT) results in a cata-
strophic and irreversible failure of DNA repair system, suggest-
ing that S-nitrosylation may contribute to cancer development
through its indirect role in preventing routine DNA repair in
otherwise normal cellular systems (53). RNS-induced PTM may
affect important physiological processes such as apoptosis and
autophagy that promote tumor onset and neoplastic evolution.
Autophagy is a cellular process of turnover for useless proteins
and organelles, which is exploited by tumor cells to survive under
conditions of metabolic stress, such as oxidizing environments
and nutrient starvation (54). Through autophagy cells may sur-
vive for a while, by progressively shrinking in size and reducing
their metabolism; however, they eventually die if better conditions
do not occur; thus autophagy can be considered a temporary and
reversible path to cell death. It has been shown that RNS induces
autophagy through suppression of mTORC1 pathway decreasing
cell viability in MCF-7 breast cancer cell line (55).
All these modifications can also modulate immunological
responses and impair any immune-based cancer therapeutic
approach; for this reason, in this review, we will focus on the gen-
eration, the biological role and the possible strategies to identify
proteins subjected to PTM and nitrosative stress in order to design
new diagnostic tools and target RNS in tumor microenvironment.
FACTORS PROMOTING RNS GENERATION IN TUMOR
MICROENVIRONMENT DURING CANCER PROGRESSION
Reactive nitrogen species generation relies on the expression and
activity of three main enzymes: NADPH oxidase (NOX), NOS,
and ARG. Although contribution of malignant cell to perox-
ynitrite production is possible, most of the nitrosative stress is
considered a reflection of the activation of these specific enzymes
in tumor-infiltrating myeloid cells, such as TAMs and MDSCs.
NADPH OXIDASE 2
NADPH oxidase 2 (NOX2) is mainly expressed in leukocytes and
endothelial cells (56) and it is activated via interaction of vascular
endothelial growth factor (VEGF) with VEGFR, tumor necro-
sis factor (TNF)-α with TNFR1, and angiopoietin with tyrosine
kinase with immunoglobulin and epidermal growth factor (EGF)
homology domains (Tie) 2 (57). Signal transducer and activator of
transcription STAT3 directly regulates the expression of both reg-
ulatory (p47phox) and catalytic (gp91phox) NOX2 subunits (58)
and controls the synthesis of S100A8 and S100A9, which poten-
tiate NOX2 activity (59). Similarly, IFN-γ up-regulates NOX2 via
JAK/STAT1 pathway (60). Interestingly, the protein complex activ-
ity is finely tuned by other post-translational mechanisms, such as
phosphorylation patterns and subunits availability (61).
iNOS/NOS2
iNOS/NOS2 expression is mainly regulated at the transcription
level and the nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) represents the central switch. In response
to specific signals, NF-κB is released from IκB and it can translo-
cate to the nucleus, promoting the transcription of downstream
genes (62). As demonstrated by mutational analysis, NF-κB acts
through multiple binding sites on iNos promoter, suggesting a
modulation of the response proportional to its availability, which
in turn is regulated by immune stimulatory signals such as LPS,
IL-1β, TNF-α, IFN-γ, and oxidative stress (63). Conversely, TGF-β,
antioxidants and glucocorticoids inhibit NF-κB and, consequently,
iNOS synthesis (64). iNos promoter comprises binding sites for
other transcription factors including CCAAT/enhancer-binding
protein (c/EBP), activation protein (AP)-1, interferon regulatory
factor (IRF)-1, p53, STAT3, and octamer factors (65–69). Inter-
estingly, cellular iNOS concentration is finely tuned also at a
translational and post-translational level by either loss of stabi-
lizing proteins at 3′ untranslated region of iNos mRNA (70, 71)
or increase in iNOS turnover in response to caveolin-1, TGF-β,
peroxisome proliferator-activated receptor (PPAR)-α agonist, and
calpain (72–77).
ARGINASES
Arginases exist as two isoenzymes in mammals, ARG1 and ARG2
differing for cellular expression/localization and for immunolog-
ical properties (78). ARG1 takes part in the urea cycle in the liver
and it is localized in the cytoplasm, whereas ARG2 is a mitochondr-
ial protein mostly present in kidney, prostate, and small intestine,
where the urea cycle is not complete. STAT6 and c/EBPβ are the
main transcription factors controlling arginases in myeloid cells
(79). ARG1 expression can be regulated by the cytokines IL-4,
IL-10, and IL-13 inducing the interaction of PU.1, STAT 6, and
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c/EBPβ transcription factors on the enhancer element of Arg1
promoter (80). Mouse Arg1 is also regulated by COX2-dependent
PGE2 overproduction (81) and by macrophage stimulating pro-
tein (MSP) (82). At a post-translational level, ARG1 is stabilized
by S-nitrosylation on Cys303 residue, which can depend on an
increased iNOS activity (83). All the molecular pathways listed
above participate in regulating ROS and RNS-producing enzymes.
As further discussed below, cancer exploits these mechanisms
pushing the balance toward the expression of NOX, iNOS, and
ARG1 with the purpose of increasing ROS and RNS levels tailoring
a microenvironment that promotes immune privileged conditions
and can sustain its unrestricted growth.
One of the strategies developed by neoplastic cells in tuning
the immune system is based on the release of factors that promote
the expression of RNS-generating molecules, i.e., HIF1-α, which
rises after exposure to hypoxic environments. The synthesis of
angiogenic factors (such as VEGF) is promoted by HIF1-α, a tran-
scription factor that is usually quickly degraded in the proteasome
after the hydroxylation carried out by the poly hydroxyl domain
(PHD) proteins under normal oxygen conditions (84). Current
data underline how HIF1-αmay trigger broader effects than those
related to angiogenesis and support tumor growth also by promot-
ing local immune suppression. The hypoxic tumor microenviron-
ment is indeed able to modify the phenotype of MDSCs by increas-
ing their immunosuppressive properties and promoting their dif-
ferentiation to TAMs. Exposure to hypoxia was shown to increase
ARG1 and iNOS expression in MDSCs with subsequent produc-
tion of peroxynitrite and their conversion from antigen-specific
to non-specific suppressors of T cell function, a phenomenon
mediated by HIF1-α (85). Moreover, hypoxia up-regulates NOX2,
iNOS, and ARG1 in many cell types (86). The mechanism under-
neath the modification of iNOS and ARG1 expression in MDSCs
is based on the regulation of NF-κB. The iNos promoter contains
also a hypoxia response enhancer (HRE) sequence, which potenti-
ates NF-κB-dependent iNOS up-regulation in macrophages (87).
Consistent data highlight the role of macrophage-derived-HIF1α
in generating a localized immune privileged site within the tumor
milieu via iNOS and ARG1 induction (88). Furthermore, the
increased production of NO establishes a positive feedback loop
on HIF1-α levels: NO-dependent impaired activity of PHD stabi-
lizes HIF1-α and NF-κB, thus amplifying the expression of genes
under their control, even under physiologic oxygen environments
(89). These observations should be taken into consideration for
designing new anti-angiogenic, immunotherapeutic approaches
based on HIF1-α-targeting to improve the efficacy of the already
available anti-VEGF therapies.
In tumor microenvironment cytokines and chemokines con-
tribute to RNS-mediated myeloid immune suppression by mul-
tiple strategies. First of all, they can influence hematopoiesis
toward the differentiation of progenitors to MDSCs and TAMs
(90) and orchestrate MDSC trafficking to peripheral tissues (i.e.,
to the tumor) (91). Second, they can tune the expression of iNOS
and ARG1. This is the case of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-6. GM-CSF stimulates the
maturation of mouse hematopoietic progenitors to DCs when
used alone, and to MDSCs in combination with IL-6 (90). How-
ever, GM-CSF binding to its receptor activates different signaling
cascades including JAK/STAT, mitogen-activated protein kinase
MAPK, and NFκB (92) whereas IL-6 mainly induces MDSC dif-
ferentiation by STAT3 activation (93). The selective induction of
iNOS, ARG1, or both depends on which cytokines are involved.
For example, during a pathogen infection, macrophages exclu-
sively up-regulate iNOS to increase their microbicidial activity in
response to pathogen-associated molecular patterns and a Th1
inflammatory stimulus like IFN-γ, IL-12, and TNF-α. This phe-
notype is mediated by NF-κB activation and binding of the IRF-1
element of the iNos promoter (94). Th1 cytokine release is a char-
acteristic of classic macrophage activation and plays a fundamental
role in central immunity stimulation. On the contrary, alterna-
tive macrophage activation, which promotes humoral immunity,
allergic and antiparasitic responses, tissue repair, and fibrosis is
linked to release of Th2 cytokines, such as IL-4, IL-10, and IL-
13 cytokines, which are responsible for ARG1 up-regulation as
well as iNOS down regulation (95). This phenotype is a gen-
eral feature shared with DCs and granulocytes (96) and is the
result of the coordinated action of PU.1 STAT6 and c/EBPβ
transcription factors (97) on Arg1 promoter. Cytokines can act
also indirectly on myeloid cells modifying their sensitivity to
either Th1 or Th2 stimuli. IL-23, for example, can increase Th2-
mediated ARG1 induction by up-regulating IL-4-Rα and IL-13-
Rα1 chains (98). Moreover, the induction and the activity of
l-Arg-metabolizing enzymes are both regulated by other intra-
cellular biochemical pathways and by competition for the same
substrate, the amino acid l-Arg (99). Anti-inflammatory cytokines
(i.e., TGF-β or IL-10) tune the iNOS/ARG1 balance toward the
up-regulation of the latter. TGF-β is a pleiotropic cytokine that
possess either inflammatory or regulatory properties depending
on the cellular and environmental context (100); however, TGF-
β can mediate immune suppression by indirect mechanisms, for
example, increasing ARG1 activity and decreasing iNOS expres-
sion that limits macrophage-dependent cytostasis of fibrosarcoma
cells (101). Interestingly, TGF-β-driven iNOS down regulation is
mediated by an increase of ELK3, a transcription repressor which
decreases the expression of iNos gene after binding to its promoter
sequence (102).
There are some important exceptions in cytokine-mediated
tuning of iNOS and ARG1 expression, which make the definition
of either classical or alternative macrophage activation in the regu-
lation of the two genes rather simplistic and sometimes inaccurate.
In mouse macrophages, LPS, a bacterial product commonly asso-
ciated with Th1 cytokine release, is able to activate both enzymes.
Moreover, in tumor environment myeloid cells can restrain T cell
functionality by up-regulating both enzymes. The concomitant
activity of ARG1 and iNOS is a peculiar property of MDSCs, or
at least of a subset of this heterogeneous population of suppressor
cells induced by tumors in mice and humans (26, 103, 104). The
molecular bases for the synergism might involve a double cross-
talk occurring during the encounter of T cells and MDSCs. IFN-γ
released by antigen-activated CD8+ T cells is the primary (but not
unique) trigger for autocrine production of IFN-γ and IL-13 by
MDSCs. These cytokines are then necessary to provide a sustained
expression and activation of both iNOS and ARG1, for a sufficient
time to affect T lymphocyte proliferation and survival (103). This
scenario reconciles the needs of both limiting the extent of T cell
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suicide/inactivation only to those cells that are activated by the
antigen and fully arm the suppressive program in MDSCs (103);
furthermore, IFN-γ produced by activated MDSCs primes other
nearby MDSCs, even though this could be limited by the necessity
of a cell–cell contact with antigen-activated CD8+ T lymphocytes
(13, 103). It is also clear that different T cell responses, biased
toward either a Th1 or Th2 type cytokine production, might selec-
tively activate either NOS- or ARG-dependent immune regulation,
respectively.
IMMUNE SUPPRESSION PROMOTED BY RNS IN TUMOR
MILIEU
A number of evidence indicates that peroxynitrite is toxic for lym-
phocytes and can prime T cells to undergo apoptotic death through
different pathways involving inhibition of protein tyrosine phos-
phorylation via nitration of tyrosine residues (105) or by nitration
of the voltage-dependent anion channel protein, a component of
mitochondrial permeability transition pore (106). Nitrotyrosine,
a marker of nitrative stress in tissues, is found in thymic extracts
and thymic sections and co-localized with apoptotic cells, suggest-
ing that RNS are also involved in thymic apoptosis in vivo (107).
However, molecular explanations on how peroxynitrite released
by myeloid cells can induce tolerance in antigen-specific CD8+ T
cells were provided only recently.
Peroxynitrite interferes with peptide binding efficiency of MHC
class I molecules as result of MHC class I and ligand–peptide com-
plex nitration/nitrosylation on tumor cells; this aspect is only a part
of the immunosuppressive barrier generated by MDSCs to impair
tumor-specific immune responses. Neoplastic cell precondition-
ing with peroxynitrite in vitro reduces immunogenic peptide–
MHC (pMHC) complex formation without affecting MHC class
I expression on cell surface resulting in impaired recognition of
tumor cells by CTLs. This effect was observed either for naturally
processed or synthetic peptides. Peroxynitrite modifies the α chain
of the MHC class I molecule only if the latter is not already loaded
with an epitome peptide. This hypothesis was initially proved using
artificially transduced antigen (OVA peptide) and confirmed with
naturally processed melanoma antigen gp100 (108). Since nitrated
proteins are mainly localized in sub-cellular compartments, like in
peroxisome-containing granules, mitochondria, and endoplasmic
reticulum (109), it is conceivable that the MHC class I α chain
is nitrated/nitrosylated by peroxynitrite in the endoplasmic retic-
ulum, just before assembly with β2 microglobulin and antigenic
peptide. Nitration/nitrosylation can also affect immunogenic pep-
tides, reducing their binding to MHC molecules. The conversion of
tyrosine residues to nitrotyrosine on peptide epitopes could influ-
ence either TCR-contact or MHC class I and II contact positions,
with profound impact on T cell responses (110–112). Elevated lev-
els of nitrated proteins have been detected in patients with different
type of cancers, i.e., bladder, colorectal, breast, and lung carci-
noma, melanoma and Hodgkin lymphoma (111). In addition, in
a transplantable model of mouse fibrosarcoma showing extensive
myeloid cell infiltration, high levels of nitrotyrosines were found
in both cytoplasm and nuclei of tumor cells (113). In the pres-
ence of RNS, such as in tumor microenvironment, the likelihood
for a peptide epitope to be subjected to nitration/nitrosylation
events seems thus quite high. Similarly, nitrogen-induced PTM of
proteins can break the tolerance toward self-antigens and initiate
autoimmune diseases. A cytochrome C-derived epitope encom-
passing nitrotyrosine in position 97 was shown to trigger a T
cell restricted immune response against the self-protein (110).
Accordingly, activated antigen presenting cells (APCs) were capa-
ble of stimulating CD4+ T lymphocytes with chemically modified
peptides (114). Thus, from a therapeutic point of view, PTM of
proteins and peptides may be exploited to break the tolerance
against weak tumor-associated antigens.
Alternatively, peroxynitrite can act on the TCR side by nitrat-
ing/nitrosylating α and β subunits and the CD8 co-receptor
molecule (115): in vitro and in vivo experiments confirmed the
molecular modeling predictions of tyrosine residues susceptible
to nitration. These modifications impair recognition of pMHC
complex and promote dissociation of the CD3 ζ chain from the αβ
TCR complex, thus disrupting TCR signaling (116). RNS action on
T cells does not appear to be limited to nitration/nitrosylation of
the crucial molecules α/β TCR, CD3, and CD8 but it also involves
a TCR ligand-independent, transient tyrosine phosphorylation
of the CD3 ζ chain, sustained for about 24 h, which delivers an
abortive signal preventing further T cell activation by TCR ligands
(117). In addition, a rapid down regulation of CD4 and CD8 co-
receptors was observed following T cell exposure to RNS (117). In
peripheral lymphoid organs, all the inhibitory effects promoted by
MDSC-secreted RNS are primarily directed toward naïve T cells
bearing the TCRs recognizing the pMHC complexes presented
by MDSCs. Some experiments indicate that MDSCs are able to
present tumor antigens to specific CD8+ T cells and in this con-
text they should facilitate exposure of TCR to the action of the
peroxynitrite they secrete. Failure to respond to stimulation with
a specific peptide was observed only for CD8+ T cells nitrated at
TCR/CD8 complex. T cells recognizing pMHC complexes differ-
ent from those expressed on MDSC surface showed less TCR/CD8
nitration and retained the ability to respond to antigens presented
by classic APCs. These data indicate that T cells with high affinity
TCRs for pMHC complexes presented by MDSCs are more prone
to peroxynitrite-dependent inhibition by MDSCs (115, 116).
Another RNS-promoted mechanism of immune suppression
relies on the modification of chemokines. As a result of RNS
exposure, these molecules might undergo PTM that alter their
chemotactic properties, impairing the recruitment of T cells and
keeping them at the periphery of the tumor lesion, unable to reach
the tumor core and exert their cytotoxic action (118). Chemokines
are organized in a complex and dynamic network, which coordi-
nates leukocyte trafficking both under physiological and patho-
logical conditions. To perform their action these proteins bind to
specific receptors associated to heterotrimeric G proteins, which
are present heterogeneously on all leukocytes (119–121). Receptor
activation leads to the triggering of signaling pathways including
inositol-phosphate 3-kinase (IP3K) and NF-κB transcription fac-
tor. The signaling cascade activates a series of events ending in
a rapid remodeling of the cytoskeleton, with increase in integrins
and adhesion molecules that promote adhesion, extravasation, and
leukocyte migration to the target sites (119). Normal chemokines
activity is also regulated by PTM such as proteolytic processing,
glycosylation, and deamination (122, 123). RNS inhibit migration
of T lymphocytes induced by some chemokines, such as CXCL12,
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CCL21, CCL2, and CCL5. RNS can down-regulate the expres-
sion of CXCR4 on T cells through alteration of the TCR/CD3
signaling complex and reduce CXCL12–induced T cell migration
(124). When exposed to the action of RNS, mouse and human
CCL2 become nitrated at the level of tyrosine and tryptophan
residues respectively; CXCL12, is subjected to tyrosine nitration
as well. This PTM reduces the binding affinity of CCL2 to its
receptor CCR2, affecting drastically tumor homing of CD8+ T
lymphocytes. Nitrotyrosines are found in tissue sections of hyper-
plastic human lymph nodes obtained from surgical resections of
patients with lung, colon, and prostate cancer (105, 124). Surpris-
ingly, the nitrated/nitrosylated CCL2 does not lose the ability to
recruit MDSCs to the tumor, likely due to higher expression of
CCR2 in myeloid than in T cells (118).
AVAILABLE TECHNOLOGIES AND NEW APPROACHES FOR
IDENTIFICATION OF NITROGEN-INDUCED PTM
Nitrogen-induced PTM is a process promoted by oxidative envi-
ronments in presence of NO and associated with a number of
different diseases such as autoimmunity (125), neurodegenera-
tive disorders (126), and cancer (118). Exactly like other PTM
(i.e., phosphorylation/dephosphorylation), RNS action on tar-
get proteins modifies their biochemical properties. Indeed 3-
nitrotyrosine, the most common and studied RNS-derived PTM,
shows peculiar chemical characteristics, which makes it different
from normal tyrosine (127) and can modify the protein tertiary
and quaternary structure, and therefore its activity. Given the
clinical relevance of PTM and 3-nitrotyrosine, many efforts have
been done in designing and developing tools to identify which
proteins are subjected to NO modification, the position of the
chemical alteration, and its biological role. Many of them are
based on the use of chromatography [i.e., HPLC: Ref. (128)] or
mass spectrometry (129), or both (130). These techniques are also
reviewed elsewhere (131). However, a major issue in defining the
“nitrome” is related to the very low representation of nitrogen-
induced PTM within the microenvironment. Indeed, only few
tyrosines are modified in vivo under inflammatory conditions:
in this context the specificity and resolution of the detection tech-
nologies may represent a limiting factor (132). Thus, enrichment
of nitrogen-induced PTM (such as with antibodies that specifically
bind modified proteins) represents an important technological
improvement. Accordingly, the development of 3-nitrotyrosine-
specific antibodies opened the way to a body of publications
focused on semi-quantitative analysis of 3-nitrotyrosine in com-
plex biological samples. Anti-3-nitrotyrosine antibody improved
already available methods for the identification of proteins sub-
jected to nitrogen-induced PTM in complex samples separated
through gel-based approaches. Indeed, a semi-quantitative evalua-
tion of 3-nitrotyrosine levels in complex samples can be performed
by 2D protein separation followed by transfer on filter and blot
with anti-3-nitrotyrosine antibody; furthermore the alignment
of the blot with 2D gel identifies the spots that can be excised
for further protein identification by MS. However, the strength
of this enriching technique strictly relies on the antibody spec-
ifications (i.e., affinity). Moreover, some PTM may be ignored
depending on the tridimensional availability of the 3-nitrotyrosine
residues to the antibody. Recent works provide an example of how
these innovative detection tools can be exploited to character-
ize the biological impact of nitrogen-modified proteins involved
in regulating peripheral immune response. Through the imple-
mentation of liquid chromatography and MS, in fact, mouse and
human CCL2 were found to be nitrated on tyrosine and tryp-
tophan residues upon exposure to RNS, respectively. To confirm
the biological impact of nitrogen-induced CCL2 modification, a
single-domain recombinant antibody was isolated that selectively
binds modified CCL2 and can be used for its detection (118).
Tyrosine is the preferential target of RNS attack; however,
a growing body of evidence highlights PTM of other aromatic
amino acids, such as tryptophan, which can alter protein func-
tion and cellular metabolism as well. Peroxynitrite and oxidant
environments modify human Cu, Zn-superoxide dismutase and
bovine serum albumin at tryptophan residues (133). Interest-
ingly, these modifications were associated with a 30% decrease
in SOD enzymatic activity. Moreover, RNS rich environments
promote a broader profile of chemical alterations than those
observed on tyrosines. Among them, 1-N -nitrosotryptophan and
6-nitrotryptophan (6-NO2Trp) are the most representative prod-
ucts after peroxynitrite exposure (133). However, the modest
presence of tryptophan nitration residues, compared with tyro-
sine, represents a limiting factor in the identification of pro-
teins that undergo RNS-dependent PTM. This is the result of
the lower tryptophan frequency in the primary protein struc-
ture, lower exposition to the solvent (hydrophobicity), and higher
redox potential than tyrosine. Despite of this technical issue, the
identification of nitrotryptophan-modified proteins represents a
key task since solvent exposed tryptophan usually participates in
molecule interactions. Indeed, the low amount of modified tryp-
tophan does not allow predicting the biological impact that its
alteration will cause. A recently developed antibody, which selec-
tively binds 6-NO2Trp, was successfully used in western blot to
detect and identify nitrotryptophan-containing proteins in per-
oxynitrite exposed rat pheochromocytoma cells (134). The access
to reagents, which specifically label nitrotryptophan and other
nitrogen-dependent modifications, will increase the body of data
on nitrogen-dependent PTM and provide a detailed snapshot
of the post-translational signature induced by nitrogen under
physiologic and pathologic contexts.
CLINICAL RELEVANCE OF RNS
The detection of the nitroxidative stress signature in various
human tumors and stages may provide information about its role
in tumor formation and progression. The correlation of nitration
level with clinical parameters can additionally offer prognostic
tools and allow the development of therapeutic strategies.
Expression and distribution of iNOS have been evaluated both
at the mRNA and protein level in many tumors and conflict-
ing results of these analyses have been reported (135, 136). Over
expression of iNOS is frequent in various human tumors but a cor-
relation with tumor stage, grade, or metastases, as well as with poor
prognosis is reported only in certain types of cancer. In gastric can-
cer (137) and melanoma (138), for example, iNOS level could be
a predicting biomarker for poor prognosis. Anyway, other types
of cancer show either controversial results such as in colorectal,
breast, brain, lung, and cervical cancer (139, 140) or no correlation
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at all, as in bladder carcinoma, pancreatic and cervical cancer
(141). Regarding the other two NOS isoforms, NOS3 expression
strongly correlates with iNOS presence in breast carcinoma (142)
and NOS1 has been detected in some oligodendrogliomas and
neuroblastomas cell lines (143). However, detecting the presence
of NOS protein is only an indirect method to evaluate nitroxidative
stress (144). In this respect, more accurate information is provided
by staining with anti-nitrotyrosine antibodies (145). Table 1 com-
pares nitrotyrosine staining pattern identified in different human
tumors. NOS and ARG detection are shown as well, as they are
involved both in a synergistic peroxynitrites generation and in
independent immunosuppressive activities (26, 146). Immunohis-
tochemistry (IHC) confirms that many tumors generally display
higher nitration level than control tissues. Compared to other
quantitative approaches that finely measure PTM levels, IHC can
provide the localization of the cellular type and compartment
subject to nitration: nitrotyrosine staining is usually localized in
neoplastic cells, but it is also observed at the level of stromal cells
as reported for colon, gastric, breast cancer, and mesothelioma
(147–150). Moreover, nitrotyrosine staining is mostly diffused
in the cytoplasm; additional focal nuclear pattern of staining is
described for breast, colon, gastric, and papillary thyroid cancer
(147–149, 151). The presence of the positive staining, however,
highlights the localization of tyrosine-nitrated proteins but it does
not provide any information about the source of peroxynitrite that
generates this modifications. Indeed, RNS can easily diffuse out of
the membrane and accomplish their function in a different cellular
target.
Besides qualitative observations, correlations of nitrotyrosine
staining with clinical parameters are described only for certain
tumor types and positivity is generally associated with worse out-
come. In head and neck squamous cell carcinoma, the staining
increases with tumor progression, suggesting a possible role of
peroxynitrite generation during carcinogenesis (47). In advanced
melanomas, a strong correlation exists between poor survival,
iNOS expression, and nitrotyrosine presence (138), while in a
cohort of patients with invasive breast cancer, nitrotyrosine stain-
ing correlates with lymph node metastasis and it may serve as
a significant prognostic factor for long-term survival since high
nitrotyrosine levels are related with poor overall survival (149). Lit-
erature for gastric adenocarcinoma describes heterogeneous and
controversial findings: one cohort of patients exhibited a differ-
ence in nitrotyrosine staining according to the tumor type, with
tubular carcinoma subtype showing the higher positivity (160).
In another study, a correlation was described between nitrotyro-
sine and tumor apoptosis showing that patients with high apop-
totic index, elevated iNOS expression, and nitrotyrosine had a
poor survival (148). Several factors can potentially explain tumor
differences regarding the correlation between RNS and clinical
evidences. In first instance, each tumor type can be subjected to
a peculiar nitrosative stress level depending on either the abun-
dance or type of RNS-producing cells. Moreover, tumor cells may
be more or less resistant to oxidative environments depending
on the activity of detoxifying mechanisms such as autophagy and
availability of molecules and proteins with scavenging properties.
Thus, nitrotyrosine staining is an inflammation indicator that pro-
vides useful information on the clinical outcome when used in
combination with other parameters such as the immunological
context (T cell and myeloid infiltrate, M1/M2 macrophage levels)
and local microenvironment (Th1/Th2 cytokines for instance).
In addition to clinical parameters, there are few published works
describing an association between nitrotyrosine positivity with
other biological factors linked to tumor progression. In a cohort
of pancreatic adenocarcinoma patients, in fact, the tumor environ-
ment was characterized by oxidative stress linked to the expression
of mitogen fibroblast growth factor (FGF)-1/2 and their receptors,
which all play a role in pancreatic cancer development (164). In
a group of advanced breast cancer patients, nitrotyrosine pos-
itive staining is associated with the presence of the angiogenic
factor VEGF-C (149). In prostatic cancer, NO and peroxynitrites
promote tumor growth through the suppression of anti-tumor
immune response. Accordingly tumor-infiltrating lymphocytes
(TILs) isolated from prostate cancer by using collagen gel matrix-
supported organ cultures were unresponsive to mitogen stimuli;
ex vivo prostate neoplastic cells generate peroxynitrite responsible
for tyrosine nitration in TILs and blockade of peroxynitrite pro-
duction restored TIL responsiveness (124). Similar dysfunction in
T cell proliferation when exposed to NO-producing tumor cell
line supernatants was described in colon carcinoma (157).
RNS: THERAPEUTIC IMPLICATIONS
To date, the nitrotyrosine detection in human cancer tissues does
not have a uniform relevance with respect to predicting clinical
disease progression in cancer patients. The reasons of this lack of
homogeneity are not known and might depend, in part, on the
limits in the available tools to detect nitrogen-induced PTM and
the dichotomic role played by NO (165). Specific locations and tar-
gets of tyrosine nitration need to be clearly identified in order to
understand in full the biological impact of PTM and find potential
candidates for new therapeutic approaches. In glioblastoma multi-
forme (GBM), for example, the key tumor suppressor protein p53
exhibits peroxynitrite-mediated modifications in vivo and, more-
over, malignant glioma cell lines treated with peroxynitrite show
wild-type p53 function inhibition (153, 154). Strategies designed
to target RNS and restore p53 functionality in tumor cells are thus
one example of a promising field of research with translational
outcomes.
As discussed above, the l-Arg metabolizing enzymes NOS and
ARG are key enzymes for the nitrogen-induced immunosuppres-
sive properties of MDSCs and TAMs. In an in vitro model of
human prostate carcinoma, only the contemporary inhibition of
ARG and NOS with NG-hydroxyl-l-arginine (NOHA) and l-
NG-monomethyl arginine citrate (l-NMMA) respectively, was
effective in reducing intratumoral nitrotyrosine staining and this
directly correlated with the ability in restoring TIL responsiveness
to various stimuli (124). In untreated cultures, in fact, prostate
TILs did not react either to antigens or signals bypassing TCR bind-
ing, indicating profound state of immune dormancy/anergy (124).
Overall, mouse and human studies have clearly recommended
that drugs aimed at reverting T lymphocyte unresponsiveness in
tumor-bearing hosts should target both ARG and NOS. The phar-
macological approach manipulating l-Arg metabolism via ARG1
and iNOS have shown therapeutic potential in preclinical stud-
ies, suggesting its use as adjuvant in combination with treatments
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Table 1 | Nitrotyrosine presence in human cancers.
Type of cancer Nitrotyrosine staining pattern Clinical and/or experimental correlation NOS/ARG
isoforms
Reference
Pancreatic
adenocarcinoma
Increased staining for iNOS and
nitrotyrosine in the ductal epithelium
of pancreatic tumor tissue
Enhanced expression of FGF-1/2 and FGF receptors
associated with an environment of oxidative stress.
Tyrosine-nitrated c-Src found only in patient tissues
iNOS (152)
Prostate cancer Increased staining for nitrotyrosine in
the epithelial cancer cells, some hot
spots in the TILs
Dysfunctional in situ TIL responses iNOS/ARG2 (124)
Glioblastoma Increased staining for nitrotyrosine in
glioma cells and possibly in
passenger leukocytes
Inhibition of wild-type p53 function in malignant
glioma cells
NOS1/iNOS (143, 153,
154)
Lung squamous cell
carcinoma and well
differentiated
adenocarcinoma
Increased staining for nitrotyrosine in
tumor cells but not in adjacent normal
areas
Nitration of metabolic enzymes, structural proteins,
and proteins involved in prevention of oxidative
damage
NOS3/iNOS (155)
Head and neck
squamous cell
carcinoma
Increased staining for nitrotyrosine in
tumor cells
Increased nitrotyrosine staining in the progression of
oral mucosa from normal to dysplastic and neoplastic
changes
NOS3 and
iNOS
(47, 156)
Mesothelioma Diffuse and variable cytoplasmic
nitrotyrosine staining for both cancer
and stromal cells
More intense nitrotyrosine staining in mesotheliomas
with higher mitochondrial manganese superoxide
dismutase (MnSOD) expression
ND (150)
Colon cancer Cytoplasmic and nuclear nitrotyrosine
staining in cancer and stromal cells
Reduction of PHA-dependent proliferation of human T
lymphocytes in the presence of supernatant from a
culture of cytokine-induced, NO-producing colon
carcinoma cells
iNOS (147, 157)
Breast cancer Diffuse cytoplasmic and focal nuclear
nitrotyrosine staining for cancer cells,
stromal macrophages and neutrophils
Correlation between high nitrotyrosine staining and
VEGF-C immunoreactivity and lymph node metastasis;
nitrotyrosine staining proposed as an independent
prognostic value for overall survival
ND (149)
Melanoma Weak to strong diffuse and
paranuclear staining of melanoma
cells
Strong correlation between poor survival with iNOS
and nitrotyrosine expression by melanoma cells in
patients with stage III disease
iNOS (138)
Papillary thyroid
carcinoma (PTC)
Weak to high-grade staining in the
cytoplasm and focally in the nucleus
in PTC cells
High-grade nitrotyrosine staining was correlated with
VEGF-D immunoreactivity and lymph node metastasis
iNOS (151, 158)
Bladder carcinoma Nitrotyrosine staining mainly in
endothelial cells and certain stromal
cells of malignant bladder tumors;
weak staining in tumor cells
ND iNOS/NOS3 (159)
Gastric
adenocarcinoma
Cytoplasmic and nuclear nitrotyrosine
staining in tumor and adjacent
stromal cells
Expression of iNOS and nitrotyrosine with a high AI is
associated with a poor survival; correlation of both
iNOS and nitrotyrosine with cancer subtype
(prevalence in tubular carcinoma) but no significance
correlation with clinical parameters
iNOS (148, 160)
Renal cancer Nitrotyrosine staining mainly in tumor
cells, but occasionally also in stroma
and in the tubular cells of
non-neoplastic renal tissue
Nitrotyrosine associated with high-grade tumors ND (161)
(Continued)
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Table 1 | Continued
Type of cancer Nitrotyrosine staining pattern Clinical and/or experimental correlation NOS/ARG
isoforms
Reference
Gynecological
cancer
Moderate nitrotyrosine cytoplasmic
staining in most of invasive ovarian
carcinomas
In invasive ovarian carcinomas there is no association
with any clinico-pathological parameters, whereas it
was observed a strong correlation with expression of
the antioxidant enzymes peroxiredoxin IV and
thioredoxin
iNOS (162, 163)
ND, not determined; 8-OHdG, 8-hydroxydeoxyguanosine; VEGF, vascular endothelial growth factor; MnSOD, mitochondrial manganese superoxide dismutase; TILs,
tumor-infiltrating lymphocytes; AI, apoptotic index.
that directly enhance the immune response. NO-donating drugs
such as nitroaspirin (classic aspirin molecule covalently linked
to a NO donor group) inhibit iNOS through various mecha-
nisms (166, 167). MDSC-derived immune suppression could be
relieved either by nitroaspirin, the combination of ARG and NOS
inhibitors, or peroxynitrite scavengers, whereas simple NO-donors
or nitroaspirin analogs lacking the NO-donating group were inef-
fective (168). The salicylic portion (with the attached spacer) of
nitroaspirin was necessary for ARG1 blockade whereas NO dona-
tion was important for the feedback inhibition of iNOS (166,
167). In vivo administration of nitroaspirin resulted in decreased
intratumoral staining with anti-nitrotyrosine and anti-iNOS anti-
bodies, together with a reduced intratumoral ARG activity (168).
Despite these positive results, nitroaspirin was not effective as an
adjuvant for adoptive cell transfer therapies (ACT; unpublished
data). On the contrary, a member of a new class of NO-donating
drugs, AT38 ([3-(amino carbonyl) furoxan-4-yl]methyl salicy-
late), was shown to increase adoptive cell therapy effects. This
compound is able to revert RNS-induced PTM of chemokines
necessary for T cell tumor invasion (118) and to reduce the in vivo
generation of peroxynitrite that can impair T cell migration to the
tumor. Interestingly, RNS targeting might represent a new inno-
vative therapeutic strategy for a broad spectrum of RNS-induced
diseases, like neurodegenerative and cardiovascular one. AT38 effi-
cacy, in fact, is not limited to the tumor microenvironment but
can be useful more in general within an inflammation context.
In a mouse model of epicutaneous vaccinia virus infection, AT38
treatment restored CD8+ T cell relocation to epidermal foci, sug-
gesting that peroxynitrite production control CD8+ T cell entry,
and consequent activity, into viral lesions (169).
As described above, intratumoral ARG activity can be sustained
by other factors, such as COX,acting on tumor-infiltrating myeloid
cells. In several preclinical trials the use of COX2 inhibitors, such
as celecoxib, down-regulated ARG1 expression, delayed tumor
growth, and stimulated anti-tumor response (81, 170–172). In
a mouse model of mesothelioma, Celecoxib improved survival
when used in combination with DC-based immunotherapy (172).
Moreover, inhibition of ARG1 and iNOS activity in MDSCs can
be achieved by phosphodiesterase-5 (PDE5) inhibitors (silde-
nafil, tadalafil, and vardenafil), which can restore the sponta-
neous anti-tumor T cell response (173). N (6)-(1-iminoethyl)-l-
lysine-dihydrochloride (l-nil) is an iNOS-selective small mole-
cule antagonist that showed potent anti-proliferative properties
on melanoma cells increasing survival in tumor-bearing mice
in combination with chemotherapy (174). To improve cellu-
lar antioxidant properties, thus limiting ROS and RNS genera-
tion, a group of anti-inflammatory molecules can represent an
alternative option: they are synthetic triterpenoids that activate
a transcription factor regulating antioxidant genes, the nuclear
factor (erythroid-derived 2)-like 2. The synthetic triterpenoid
CDDOMe reduced ROS and peroxynitrite levels in MDSCs and
abrogated MDSC-dependent immune suppression both in several
tumor mouse models and in pancreatic cancer patient; however,
ARG activity or NO levels were not affected in MDSCs (175).
It is thus possible to exploit in current therapeutic protocols,
the association of different drugs affecting either concurrent or
alternative steps in the biochemical production of peroxynitrite.
Other antioxidant compounds have been validated in vitro and
are currently investigated as candidates for cancer therapy. For
instance, 3,4′,5-trihydroxy-trans-stilbene (resveratrol), a polyphe-
nolic natural product described as free radical scavenger was able
to induce apoptosis in several cell lines by regulating proteins that
patrol cell cycle such as p53 and cyclin dependent kinases (176–
178). Accordingly, diferuloylmethane (curcumin) showed similar
properties in vitro. This phenolic compound can be considered
more than just an oxidant scavenger molecule since it inhibits
the NF-κB activation reducing iNOS and DNA-dependent pro-
tein kinase catalytic subunit levels; additionally curcumin induces
the up-regulation of p21, p27, p53, and the checkpoint kinase 2
expression, thus promoting the G2/M cycle arrest and apoptosis in
human melanoma cell lines (179). Given their similar biological
properties, resveratrol and curcumin have been tested together
in different set-ups with promising results; their combination
was able to reduce the proliferation of Hepa 1–6 hepatocellular
tumor cells in vitro (180) and of HCT-116 colon cancer cells,
in vivo (181).
As described above, nitrosative stress plays a role in regu-
lating autophagy in MCF-7 breast tumor cells (55), therefore
therapeutic approaches targeting this pathway can be also con-
sidered. Autophagy, indeed, is a double-edged sword, which can
either promote or control tumor progression; when this process
is impaired, cells become more sensitive to RNS and oxidative
conditions resulting in higher accumulation of genetic alterations,
which increase both apoptosis and neoplastic evolution. From the
other side sustained autophagy progressively depletes cells from
proteins, membranes, and organelles until death. Therefore this
process can be exploited to promote tumor apoptosis by using
autophagy activators, such as rapamycin (54).
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FIGURE 2 |The generation of RNS in tumor environment induces
PTM that alter immune responses to tumors. (A) MDSC and
tumor cells express high level of NOX, ARG1, iNOS and produce large
amount of RNS. RNS induce nitration/nitrosylation of either MHC
class I molecules or peptide ligands on tumor cells and TCR chains on
T lymphocytes, thus resulting in impaired recognition of tumor cells.
RNS also modify chemotactic proprieties of chemokines. CCL2
nitration reduces the binding affinity to its receptor, CCR2, drastically
affecting tumor homing of CD8+ T lymphocytes. All these
modifications alter the recruitment of T cells and their cytotoxic
function. (B) Administration of molecules AT38, L-NMMA, PDE5,
Celecoxib, and CDDOMe through the enzymatic inhibition of NOX,
ARG and NOS blocks nitration/nitrosylation, restores immune
functions, and increases lymphocyte infiltration.
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In conclusion, based on published data, many agents have
shown potential benefits in combination with immunotherapy
in preclinical studies. l-Arg metabolism manipulation via ARG
and NOS can contribute in the regulation of tumor-infiltrating
immune cells, reducing MDSC accumulation and promoting T
cell infiltration (81, 118, 168, 170), thus representing a potential
adjuvant for immune therapeutic approaches. However, before
reaching the clinic, further knowledge is necessary, such as the
evaluation of systemic side effects and the assessment of cancer
types that would receive a real benefit after modulation of l-Arg
metabolism.
Figure 2 summarizes MDSC activity in tumor environment
(Figure 2A) and the effects of the above mentioned inhibitory
compounds (Figure 2B).
CONCLUSION
Reactive nitrogen species-induced modifications of proteins play
a critical role in distracting the immune system from recognizing
and eliminating tumor cells, and most likely act as an important
barrier that limits the effectiveness of immunotherapy approaches.
Targeting RNS can substantially improve the effect of cancer
immune therapy and also their detection could be used as bio-
marker to define the prognosis and evaluate the clinical outcome of
patients. In many types of cancer, tumor-infiltrating myeloid cells,
such as MDSCs and TAMs, act as the major source of RNS in tumor
tissues. Therefore, their elimination or functional block could also
contribute to a fundamental reduction in RNS. Although several
mechanisms of RNS-mediated effects on the immune system in
cancer have been suggested, the underlying molecular processes
need further elucidation. In this context, the development of
new tools for the identification of nitrogen-induced PTM will
allow clinicians and researchers to provide a signature of nitrated
proteins, impaired signaling pathways, and cellular dysfunctions
activated by those modifications under specific pathologic condi-
tions, opening the way to a more customized therapeutic inter-
vention. New cancer treatment protocols include combinatorial
approaches such as tumor microenvironment preconditioning to
eliminate patient immune dormancy. In this scenario, targeting
RNS-induced PTM represents a new emerging frontier of com-
binatorial cancer therapy that can improve the efficacy of either
active or passive immunotherapy.
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